Unknown

Dataset Information

0

Human induced pluripotent stem cell-derived mesenchymal stem cells prevent adriamycin nephropathy in mice.


ABSTRACT: Human induced pluripotent stem cell-derived mesenchymal stem cells (iPS-MSCs) are emerging as attractive options for use in cell replacement therapy, but their effect in kidney diseases remains unknown. Here, we showed that intravenous injection of iPS-MSCs protect against renal function loss in both short-term and long-term models of adriamycin nephropathy (AN). In the short-term AN model, iPS-MSCs conferred a substantial anti-apoptotic effect on tubular cells, associated with a downregulation of Bax and Bax/Bcl2 ratio and an upregulation of survivin expression. In vitro, conditioned medium from iPS-MSCs (iPSMSC-CM) significantly limited albumin-induced tubular apoptosis and enhanced tubular proliferation, accompanied by a reduced expression of tubular Bax and an elevated expression of Bcl2 and survivin. Oxidative stress was markedly attenuated by iPS-MSCs both in AN mice and in protein-overloaded tubular cells. In the long-term AN model, repeated injections of iPS-MSCs significantly inhibited tubulointerstitial fibrosis and reduced intrarenal deposition of collagen I, collagen IV and ?SMA. Modulation of the hedgehog signaling pathway contributed to the anti-fibrotic effect of iPS-MSCs in chronic AN. Finally, we detected that most of the infused iPS-MSCs were entrapped in the lungs. In conclusion, our data support a beneficial role of iPS-MSCs in both acute and chronic AN.

SUBMITTER: Wu HJ 

PROVIDER: S-EPMC5732756 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Human induced pluripotent stem cell-derived mesenchymal stem cells prevent adriamycin nephropathy in mice.

Wu Hao Jia HJ   Yiu Wai Han WH   Wong Dickson W L DWL   Li Rui Xi RX   Chan Loretta Y Y LYY   Leung Joseph C K JCK   Zhang Yuelin Y   Lian Qizhou Q   Lai Kar Neng KN   Tse Hung Fat HF   Tang Sydney C W SCW  

Oncotarget 20171010 61


Human induced pluripotent stem cell-derived mesenchymal stem cells (iPS-MSCs) are emerging as attractive options for use in cell replacement therapy, but their effect in kidney diseases remains unknown. Here, we showed that intravenous injection of iPS-MSCs protect against renal function loss in both short-term and long-term models of adriamycin nephropathy (AN). In the short-term AN model, iPS-MSCs conferred a substantial anti-apoptotic effect on tubular cells, associated with a downregulation  ...[more]

Similar Datasets

| S-EPMC3549478 | biostudies-literature
| S-EPMC8422924 | biostudies-literature
| S-EPMC8435459 | biostudies-literature
| S-EPMC8481886 | biostudies-literature
| S-EPMC4533800 | biostudies-other
| S-EPMC5984568 | biostudies-other
| S-EPMC6941757 | biostudies-literature
| S-EPMC4460911 | biostudies-literature
| S-EPMC6224789 | biostudies-literature
| S-EPMC6854018 | biostudies-literature